Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) shares gapped up before the market opened on Monday . The stock had previously closed at $2.35, but opened at $2.65. Curaleaf shares last traded at $2.88, with a volume of 643,376 shares.
Analysts Set New Price Targets
Separately, Cormark raised shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the company presently has an average rating of "Strong Buy".
Check Out Our Latest Stock Analysis on Curaleaf
Curaleaf Price Performance
The stock has a market capitalization of $1.98 billion, a PE ratio of -9.21 and a beta of 0.75. The company's fifty day simple moving average is $2.40 and its two-hundred day simple moving average is $1.41. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.70 and a current ratio of 1.47.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.61%. As a group, sell-side analysts predict that Curaleaf Holdings, Inc. will post -0.25 EPS for the current year.
About Curaleaf
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.